Oncolytic viruses (OVs) are a class of viruses that can selectively replicate in and lyse cancer cells without causing damage to normal cells. Oncolytic viruses have tremendous therapeutic potential involves both direct tumor cell lysis and the induction of immunogenic cell death (ICD). OVs encompass a broad diversity of DNA and RNA viruses, and currently used in cancer clinical trials are adenovirus, herpes simplex virus, vaccinia virus and vesicular stomatitis virus. An extensive panel of transgenes has been used to modify the oncolytic viruses' backbones to enhance their therapeutic activity in preclinical studies. Creative Biolabs provides pre-made oncolytic viruses including adenovirus (AdV), vesicular stomatitis virus (VSV), herpes simplex virus (HSV), vaccinia virus (VACV) for oncolytic virotherapy research.
Several strategies have been investigated for molecular imaging that categorized into optical and deep tissue imaging, utilizing several reporter genes encoding for fluorescence proteins, conditional enzymes, and membrane protein and transporters.
Oncolytic viruses have been engineered to express immunostimulatory genes to enhance the contribution of ICD, and can be used as cancer vaccines. OVs armed with cytokines (IL-2, IL-12, IL-15, IL-18 and IFN-α/β) and chemokines (CCL2, CCL5, CCL17) can induce antitumor immunity, as cytokines recruit T cells and regulate T cell homeostasis. Cytokine-expressing oncolytic virus can enhance immune response by promoting APC recruitment and maturation.
Immune checkpoint inhibitors aim to overcome tumor-induced immune suppression and evasion caused by the expression of immune checkpoints. Immune checkpoint antibody-armed oncolytic virus help maintain active T effector cell killing within a tumor environment, effectively allowing a sustained adaptive immunity against a tumor from development. PD1 and CTLA4 antibodies are the most widely studied in basic research and clinical trials.
Capsid-modified oncolytic virus can enhance targeting and efficacy, providing a platform for further clinical application of oncolytic virus for cancer treatment. Inducing apoptosis specifically in tumor cells without significant toxicity in normal cells, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered as a promising candidate for cancer therapy. Significantly enhanced anti-tumor effects have been detected both in vitro and in vivo by linkage of TRAIL to the oncolytic viral capsid. Creative Biolabs are devoted to improving specific and developed cell-targeted vectors for gene therapy.
miRNA consists of a single-stranded RNA fragment of 18-24 nucleotides in length which can regulate stability or translation efficiency of the target mRNA by acting as sequence-specific guides. Creative Biolabs provides pre-made oncolytic viruses for shRNA and miRNA expression which are fully verified.
Creative Biolabs has built a state-of-the-art oncolytic virus engineering platform which provides a series of purified pre-made oncolytic virus for reporter-encoding, cytokine-expressing, immune checkpoint antibody-arming, capsid-modifing and miRNA-expression. Each modified oncolytic virus has been fully verified. If you don't have enough time to make your own modified oncolytic virus, here are various high-quality pre-made oncolytic virus products which are ready-to-transfect. Creative Biolabs has a large pre-made oncolytic virus collection available to choose different transgenes and promoters, as well as advanced construction technologies to simplify and accelerate your research. If you don't find the pre-made oncolytic virus you want in the product list we provide, Creative Biolabs can also provide the customized oncolytic virus service at the best prices and fastest turnaround time for you!